{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:22:41Z","timestamp":1790011361295,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["20232BAB206176"],"award-info":[{"award-number":["20232BAB206176"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["20224BAB216114"],"award-info":[{"award-number":["20224BAB216114"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304290"],"award-info":[{"award-number":["82304290"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012259","name":"Major Discipline Academic and Technical Leaders Training Program of Jiangxi Province","doi-asserted-by":"publisher","award":["20243BCE51168"],"award-info":[{"award-number":["20243BCE51168"]}],"id":[{"id":"10.13039\/501100012259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejmech.2026.118565","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:12:34Z","timestamp":1768461154000},"page":"118565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Discover of a highly effective covalent inhibitor of CDK6 for triple-negative breast cancer treatment"],"prefix":"10.1016","volume":"305","author":[{"given":"Jingting","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fucheng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renxin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanglan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1717-1857","authenticated-orcid":false,"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118565_bib1","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3390\/ijms22062935","article-title":"Cyclin-dependent kinases (CDK) and their role in diseases development-review","volume":"22","author":"\u0141ukasik","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118565_bib2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41589-020-00725-y","article-title":"Allostery governs Cdk2 activation and differential recognition of CDK inhibitors","volume":"17","author":"Majumdar","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118565_bib3","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1021\/acs.jmedchem.1c02064","article-title":"From structure modification to drug launch: a systematic review of the ongoing development of cyclin-dependent kinase inhibitors for multiple cancer therapy","volume":"65","author":"Shi","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118565_bib4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/biomedicines10030685","article-title":"Targeting CDK4\/6 for anticancer therapy","volume":"10","author":"Qi","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2026.118565_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118565_bib6","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1158\/0008-5472.CAN-14-0584","article-title":"Definition of PKC-\u03b1, CDK6, and MET as therapeutic targets in triple-negative breast cancer","volume":"74","author":"Hsu","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118565_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.semcancer.2022.12.006","article-title":"CDK inhibitors from past to present: a new wave of cancer therapy","volume":"88","author":"Mughal","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2026.118565_bib8","first-page":"1913","article-title":"CDK inhibitors in cancer therapy, an overview of recent development","volume":"11","author":"Zhang","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118565_bib9","first-page":"286","article-title":"Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment","volume":"23","author":"Chen","year":"2025","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118565_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O'Leary","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118565_bib11","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s40262-020-00930-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib","volume":"59","author":"Groenland","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2026.118565_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101206","article-title":"Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer","volume":"14","author":"Powell","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejmech.2026.118565_bib13","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40265-021-01508-y","article-title":"Trilaciclib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118565_bib14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118565_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.118565_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106683","article-title":"Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA","volume":"139","author":"Wang","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118565_bib17","doi-asserted-by":"crossref","first-page":"21186","DOI":"10.1021\/acs.jmedchem.4c01976","article-title":"Discovery of dual CDK6\/BRD4 inhibitor inducing apoptosis and increasing the sensitivity of ferroptosis in triple-negative breast cancer","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118565_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117685","article-title":"Design, synthesis, and biological evaluation of novel CDK4\/6 and BRD4 dual inhibitors for treatment of KRAS-mutant NSCLC","volume":"292","author":"Tong","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118565_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105669","article-title":"Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3\/CDK4 inhibitors","volume":"121","author":"Li","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118565_bib20","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.1021\/acs.jmedchem.1c00159","article-title":"Discovery of PF-06873600, a CDK2\/4\/6 inhibitor for the treatment of cancer","volume":"64","author":"Freeman-Cook","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118565_bib21","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1021\/acs.jmedchem.4c01686","article-title":"Elucidating binding selectivity in cyclin-dependent kinases 4, 6, and 9: development of highly potent and selective CDK4\/9 inhibitors","volume":"68","author":"Jiang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118565_bib22","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s40265-017-0811-4","article-title":"Neratinib: first global approval","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118565_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","article-title":"Zanubrutinib: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118565_bib24","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40265-021-01574-2","article-title":"Sotorasib: first approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.118565_bib25","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1021\/acs.jmedchem.1c02134","article-title":"The Ascension of targeted covalent inhibitors","volume":"65","author":"Singh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118565_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cbpa.2017.05.008","article-title":"Covalent inhibitors: an opportunity for rational target selectivity","volume":"39","author":"Lagoutte","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118565_bib27","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1021\/acs.jmedchem.9b00387","article-title":"Application of dually activated michael acceptor to the rational design of reversible covalent inhibitor for enterovirus 71 3C protease","volume":"62","author":"Ma","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118565_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113432","article-title":"Discovery of a novel covalent CDK4\/6 inhibitor based on palbociclib scaffold","volume":"219","author":"Shan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118565_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117263","article-title":"Palbociclib and Michael-acceptor hybrid compounds as CDK4\/6 covalent inhibitors: improved potency, broad anticancer spectrum and overcoming drug resistance","volume":"84","author":"Fang","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118565_bib30","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1021\/acs.jmedchem.5c00127","article-title":"Discovery of YJZ5118: a potent and highly selective irreversible CDK12\/13 inhibitor with synergistic effects in combination with Akt inhibition","volume":"68","author":"Yang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118565_bib31","doi-asserted-by":"crossref","first-page":"15770","DOI":"10.1021\/acs.jmedchem.2c01334","article-title":"Discovery of novel N-(5-(pyridin-3-yl)-1H-indazol-3-yl) benzamide derivatives as potent cyclin-dependent kinase 7 inhibitors for the treatment of autosomal dominant polycystic kidney disease","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118565_bib32","doi-asserted-by":"crossref","first-page":"7.8.1","DOI":"10.1002\/cpph.9","article-title":"In vitro drug metabolism using liver microsomes","volume":"74","author":"Knights","year":"2016","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118565_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118565_bib34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/1871520616666161031143301","article-title":"The warburg effect and the hallmarks of cancer","volume":"17","author":"Schwartz","year":"2017","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118565_bib35","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/1097-0142(19871201)60:11<2682::AID-CNCR2820601118>3.0.CO;2-H","article-title":"Glucose utilization in vivo by human pulmonary neoplasms","volume":"60","author":"Nolop","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.118565_bib36","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1002\/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X","article-title":"Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study","volume":"72","author":"Brown","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.118565_bib37","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.semcancer.2022.09.007","article-title":"Tumor glycolysis, an essential sweet tooth of tumor cells","volume":"86","author":"Paul","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2026.118565_bib38","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.celrep.2016.05.052","article-title":"Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics","volume":"15","author":"Navarro","year":"2016","journal-title":"Cell Rep."},{"issue":"16","key":"10.1016\/j.ejmech.2026.118565_bib39","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1158\/0008-5472.CAN-17-0385","article-title":"Expression of long noncoding RNA YIYA promotes glycolysis in breast cancer","volume":"78","author":"Xing","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118565_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2049-3002-2-17","article-title":"Mitochondrial reactive oxygen species and cancer","volume":"2","author":"Sullivan","year":"2014","journal-title":"Cancer Metab"},{"key":"10.1016\/j.ejmech.2026.118565_bib41","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3109\/10715761003667554","article-title":"Reactive oxygen species in cancer","volume":"44","author":"Liou","year":"2010","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.ejmech.2026.118565_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202400591","article-title":"Prussian blue-derived nanocomposite synergized with calcium overload for three-mode ROS outbreak generation to enhance oncotherapy","volume":"13","author":"Xu","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.ejmech.2026.118565_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202312141","article-title":"Tumor microenvironment specific regulation ca-fe-nanospheres for ferroptosis-promoted domino synergistic therapy and tumor immune response","volume":"20","author":"Chu","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.ejmech.2026.118565_bib44","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.1158\/0008-5472.CAN-19-0008","article-title":"A novel MYCN-specific antigene oligonucleotide deregulates mitochondria and inhibits tumor growth in MYCN-amplified neuroblastoma","volume":"79","author":"Montemurro","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118565_bib45","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1021\/acs.jcim.9b00268","article-title":"Toward atomistic modeling of irreversible covalent inhibitor binding kinetics","volume":"59","author":"Yu","year":"2019","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118565_bib46","doi-asserted-by":"crossref","first-page":"8606","DOI":"10.1038\/s41467-024-52573-2","article-title":"Reversible covalent c-Jun N-terminal kinase inhibitors targeting a specific cysteine by precision-guided Michael-acceptor warheads","volume":"15","author":"B\u00e1lint","year":"2024","journal-title":"Nat. Commun."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T01:08:32Z","timestamp":1773536912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":46,"alternative-id":["S0223523426000103"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118565","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discover of a highly effective covalent inhibitor of CDK6 for triple-negative breast cancer treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118565"}}